We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Left-Heart Lead for Cardiac Devices

By HospiMedica staff writers
Posted on 15 May 2002
A left-heart lead that delivers resynchronization therapy for heart failure is designed to offer doctors easier access to the left side of the heart. More...


In resynchronization therapy, an implantable device delivers electrical stimulation to both sides of the heart to optimize the beating action of the lower chambers. Leads connect the implantable device to the chambers of the heart. The new lead, Attain OTW, is intended for use with the InSync and InSync ICD systems developed by Medtronic, Inc. (Minneapolis, MN, USA). The InSync system is an implantable cardiac resynchronization system, while the InSync ICD is intended to sense from the right ventricle only, preventing inappropriate shocks from double counting due to bi-ventricular sensing.
Because each patient's anatomy is unique and heart failure can result in cardiac remodeling, left-heart lead delivery can be difficult, requiring a variety of leads and delivery tools, says Medtronic. Because of its small body size and distal curves designed for ease of steering and mobility, the Attain OTW is designed to allow implanters to maneuver it through small and medium-sized cardiac veins. Medtronic states that it is the only lead of its kind that can be delivered with both a guidewire and a stylet

"The Attain OTW lead lets me choose among more cardiac veins and access them more easily,” said Bruce L. Wilkoff, M.D., director of cardiac pacing and tachyarrhythmia devices at the Cleveland Clinic Foundation (OH, USA). "This allows me to navigate to the left ventricle and place the electrode in the precise position to achieve the best result.”




Related Links:
Medtronic

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.